Abstract 

Background: Many infections in healthcare facilities are associated with the microbiological quality of the work environment, generally due to poor sanitation.

Aim: In order to evaluate the effectiveness of a decontamination protocol (cleaning + disinfection) applied at the “Université des Montagnes” Teaching Hospital, the present study assessed the variation of bacterial loads on surfaces subsequent to decontamination. Susceptibility of bacteria to disinfectants was also evaluated in the same frame.

Methodology: This work was conducted with an adjusted bacterial detection/enumeration and susceptibility test protocols and standard bacterial identification protocols. Sampling on surfaces was performed by wet swabbing before cleaning, between cleaning and disinfection and after disinfection.

Results: Major findings revealed the predominance of Staphylococcus on target surfaces (75.5%). High bacterial loads recorded on these surfaces before decontamination became undetectable after cleaning with the detergent “Pax lemon”. The majority of isolates (98%) were susceptible to the disinfectants tested, (Surfanios^® 0.25% and sodium hypochlorite 0.12%).

Conclusion: Overall, these findings indicated process effectiveness on the subjected bacterial populations and suggest the use of either Surfanios^® (0.25%) or sodium hypochlorite (0.12%) for work surfaces hygiene, justifying the use of these products in this department for surface decontamination. Also, cleaning with the detergent “Pax lemon” and disinfection with sodium hypochlorite may be sufficient for the types of surfaces subjected in the present research.

Keywords: Bacteria; Decontamination; Hospital; Surfaces

Abstract 

Title : Perivenular intracavernosal Mesenchymal stem cell ( MSC ) Isolation and storage from Corpora cavernosum and corpora spongiosum in adult male rabbit and adult dog and production of clonal MSC nanoparticulated delivery for penile condition which caused ED ( Erectile dysfunction ) in subject male rabbit and dog and check for the erection function in these male Dog and Rabbit.

AIM : To prove the association of whether clonal MSC produced in GMP grade facility has role in ED treatment has value in regenerative medicine practice in Animals and thereby in humans.

Methodology : Taking 20 dogs and Rabbit as control and 20 as subjects ( Dogs/ rabbit) DMED ( Stretozocin induced diabetic ED) Male Dogs and Male Rabbits, they are subjected to clonal delivery of nanoparticulated MSC ( Mesenchymal Stem Cells ) . The ED function can be measured by intra cavernosal pressure measurement, apomorphine test, dynamic infusion caversometry, isometric tension study. The to be Stored MSC can be isolated and expanded in culture medium . After extraction these MSC cells are expanded to estimate the cytokine and biological response modifier functions and see for cytokine levels and regeneration mechanisms.

Discussion : The nanoparticulated Intracavernosal delivery of MSC can be used if proven superior and can be a potential treatment modality form DMED dogs and Rabbit Model.

Conclusion of the Hypothesis : The perivenular MSC taken from potent male Rabbits and Dogs might be able to change the ED status , once proven histologically the treatment could have a potential impact on the treatment of Human Male ED.

Abstract 

Background: This study aimed to evaluate the safety and efficacy of allogeneic adipose-derived mesenchymal stem cells (allo-ASC) for the treatment of lateral epicondylosis (LE). Mesenchymal stem cell therapy presents a promising regenerative treatment for tendinopathy, and this trial sought to compare intra-tendon injections of allo-ASC against a control treatment.

Methods: Ten patients with LE persisting for over six months were recruited and randomly assigned to either the cell group or control group. Injections were performed under sonographic guidance, delivering 0.5 ml of thrombin with 10^6 allo-ASCs (cell group) or normal saline (control group) mixed with 0.5 ml of fibrin into the largest hypoechoic defect in the common extensor tendon. Safety assessments were conducted on day 3, and at 2, 6, 12, 24, and 48 weeks post-injection. Efficacy was measured using pain visual analogue scale (VAS) at rest and during activity, Mayo elbow performance index (MEPI), grip strength, and ultrasonographic evaluations at baseline and at 6, 12, 24 and 48 weeks post-injection. Ultrasonographic findings were rated using a 5-point Likert scale. An intention-to-treat analysis with the last observation carried forward method was employed.

Results: Five patients were assigned to the cell group and five to the control group. One control group patient dropped out before the 48-week follow-up due to aggravated calcific tendinitis of the elbow. No serious adverse events were reported. Both groups showed significant improvement in pain VAS at rest and MEPI from baseline to 48 weeks. The cell group also showed significant improvement in pain VAS during activity and grip strength, while the control group did not exhibit significant changes in these measures. No statistically significant differences were observed between the groups at any follow-up point.

Conclusion: This randomized controlled double-blind trial demonstrated that intra-tendon injection of allo-ASC significantly reduced pain during activity over a one-year follow-up compared to baseline. Both allo-ASC and fibrin glue treatments improved pain at rest and function. However, no significant differences between the treatment groups were detected. Future studies with larger sample sizes and refined criteria are recommended.

Abstract

Stem cells are increasingly used to model human disorders, employed as a tool in drug discovery and leveraged for their therapeutic value. In our lab, we have successfully developed stem cell-derived organoids or 3D cultures of the miniature liver, brain, and cartilage along with cancer stem cell models to explore many aspects of biology- molecular and cellular mechanisms, drug testing systems and transplantable cellular resources. From the perspective of regenerative medicine for developing treatment for aging associated diseases, we have developed a multiple-cell system using stem cells to study both degenerative diseases and characterise the therapeutic value of stem cells as single and combination therapy as potential treatment modalities for various degenerative conditions. In order to make stem cell transplantation a success, we have been developing rejuvenation strategies for ageing stem cells and expanding their therapeutic value by improving the stem cell bioprocessing pipeline in collaboration with industrial partners. While one arm of the lab is focusing on regenerative medicine, the other arm is dedicated to developing cancer stem cell models and key regulatory targets through integrated multi-omic bioinformatics analysis and targeted regulators that will enable the targeting of the resistant population in a tumour, therefore eradicating cancer. In this talk, I will highlight how we can leverage stem cell biology to understand disease mechanisms, modelling the diseases and leverage their potential for realising regenerative medicine, along with how stem cell may answer some of your research questions and produce a work with high scientific merit